Kane Biotech Inc. is a biotechnology company engaged in the research, development and commercialization of products that prevent and remove microbial biofilms. When protected by a biofilm, bacteria become highly resistant to antibiotics, antimicrobials, biocides and host immune responses. This resiliency contributes to numerous human health related problems with an addressable market of over $340 million USD in the US alone (Grandview Research). Kane Biotech’s mission is to commercialize within Canada and the US through distribution networks with an eye to licensing its to global industry players. Kane Biotech’s lead products are (Rrevyve® Antimicrobial Wound Gel and revyve® Antimicrobial Wound Spray which have been cleared by the US FDA and approved by Health Canada. The Company has 10 employees and is headquartered in Winnipeg, Manitoba, Canada.